— Know what they know.
Not Investment Advice

BIVI

BioVie Inc.
1W: -7.1% 1M: +1.6% 3M: -9.7% YTD: -1.5% 1Y: -87.6% 3Y: -99.9% 5Y: -99.9%
$1.20
-0.26 (-17.81%)
After Hours: $1.31 (+0.11, +9.17%)
NASDAQ · Healthcare · Biotechnology · $9.0M · Alpha Radar Buy · Power 67
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$9.0M
52W Range1.06-13.2
Volume137,793
Avg Volume111,220
Beta0.62
Dividend
Analyst Ratings
5 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOCuong Viet Do
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2020-09-18
680 West Nye Lane
Carson City, NV 89703
US
775 888 3162
About BioVie Inc.

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Recent Insider Trades

NameTypeSharesPriceDate
Palumbo Joseph M A-Award 132,000 $1.31 2026-01-05
KIM JOANNE WENDY A-Award 110,100 $1.31 2026-01-05
ROGICH SIGMUND A-Award 70,000 $1.31 2026-01-05
ROGICH SIGMUND A-Award 141,100 $1.31 2026-01-05
DO CUONG V A-Award 665,300 $1.31 2026-01-05

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms